- News
Alithea Biotechnology GmbH: Immunotherapies thanks to HLA-Compass
Alithea Biotechnology has set itself the goal of revolutionising the development of cancer therapies.
Many immunotherapies are ineffective because the target structures on cancer cells, known as HLA peptides, are difficult to identify. The Freiburg-based start-up has developed the world's largest HLA peptidome database, the HLA Compass.
By using proprietary mass spectrometry, AI and big data, the SaaS platform enables biopharmaceutical companies to develop precise and personalised therapies.
The integrated AI-supported side effect prediction also makes these therapies safer. Alithea Biotechnology is thus making a decisive contribution to bringing effective and safe immunotherapies to patients more quickly.
